Skip to main content
Man with a dog

Actor portrayal.

About EBGLYSS

Now approved for the treatment of moderate-to-severe eczema

Break away from the bothersome symptoms of eczema

Introducing EBGLYSS, a new treatment that can work continuously against eczema to restore skin and reduce itch.

EBGLYSS can provide calming itch relief and clearer skin that lasts

In two 1-year clinical studies, a majority of people who experienced clear or almost-clear skin and calming itch relief with EBGLYSS maintained those results through the end of the studies.

In an average of two studies
Many people achieved clear or almost-clear skin with EBGLYSS

clearance icon

At 16 weeks, 38% saw clear or almost-clear skin with EBGLYSS
(12% with placebo)

Some people achieved clear or almost-clear skin at 4 weeks.

calendar flipping icon

At 1 year, of the people who saw clear or almost-clear skin at 16 weeks, 77% still saw clearance
(compared with 48% who stopped EBGLYSS at week 16 and were then treated with placebo)

In an average of two studies, most people saw at least 75% clearer skin with EBGLYSS

At 16 weeks, 55% saw at least 75% clearer skin with EBGLYSS (17% with placebo)

Select Important Safety Information
Do not use EBGLYSS if you are allergic to lebrikizumab-lbkz or to any of the ingredients in EBGLYSS. See the Patient Information leaflet that comes with EBGLYSS for a complete list of ingredients.

EBGLYSS results

In studies for adults and adolescents, study patients saw clearer skin at 16 weeks.

Before Treatment

After Treatment

After Treatment - A patient with almost clear skin, chest shown.
Before Treatment - A patient image of the chest with atopic dermatitis.

Clinical trial patients treated with lebrikizumab-lbkz. Individual results may vary. © Eli Lilly and Company, 2024. All rights reserved.

Before Treatment

After Treatment

After Treatment - A patient with clear skin, back of knee shown.
Before Treatment - A patient image of the back of the knee with atopic dermatitis.

Clinical trial patients treated with lebrikizumab-lbkz. Individual results may vary. © Eli Lilly and Company, 2024. All rights reserved.

Before Treatment

After Treatment

After Treatment - A patient with almost clear skin, palm shown.
Before Treatment - A patient image of the palm with atopic dermatitis.

Clinical trial patients treated with lebrikizumab-lbkz. Individual results may vary. © Eli Lilly and Company, 2024. All rights reserved.

Before Treatment

After Treatment

After Treatment - A patient with clear skin, inside of elbow shown.
Before Treatment - A patient image of the inside elbow with atopic dermatitis.

Clinical trial patients treated with lebrikizumab-lbkz. Individual results may vary. © Eli Lilly and Company, 2024. All rights reserved.

Before Treatment

After Treatment

After Treatment - A patient with almost clear skin, hand shown
Before Treatment - A patient image of the hand with atopic dermatitis.

Clinical trial patients treated with lebrikizumab-lbkz. Individual results may vary. © Eli Lilly and Company, 2024. All rights reserved.

Before Treatment

After Treatment

After Treatment - A patient with almost clear skin, palm shown.
Before Treatment - A patient image of the palm with atopic dermatitis.

Clinical trial patients treated with lebrikizumab-lbkz. Individual results may vary. © Eli Lilly and Company, 2024. All rights reserved.

In an average of two studies, many people saw at least 90% clearer skin with EBGLYSS

At 16 weeks, 35% saw at least 90% clearer skin with EBGLYSS (9% with placebo)

Select Important Safety Information

Before using EBGLYSS, tell your healthcare provider about all your medical conditions, including if you:

  • Have a parasitic (helminth) infection.
  • Are scheduled to receive any vaccinations. You should not receive a “live vaccine” if you are treated with EBGLYSS.
  • Are pregnant or plan to become pregnant. It is not known if EBGLYSS will harm your unborn baby. If you become pregnant during treatment with EBGLYSS, you or your healthcare provider can call Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) to report the pregnancy.
  • Are breastfeeding or plan to breastfeed. It is not known if EBGLYSS passes into your breast milk.
  • Take prescription or over-the-counter medicines, vitamins, and herbal supplements.

In an average of two studies
More than 4 in 10 people felt itch relief with EBGLYSS

Itch icon

At 16 weeks, 43% felt itch relief with EBGLYSS
(12% with placebo)

Calendar flipping icon

At 1 year, of the people who felt itch relief at 16 weeks, 85% still felt relief
(compared with 66% who stopped EBGLYSS at week 16 and were then treated with placebo)

Results at 1 year are based on testing that was less rigorous, so the findings are less certain.

In one study, some people felt itch relief at 2 weeks.

Get help discussing eczema

Moderate-to-severe eczema can be unpredictable. Talking with your doctor doesn’t have to be.

Speech bubble icon

Download the Doctor Discussion GuideCaretRight

Questions about what to expect with EBGLYSS?

Watch videoCaretRight

Play button

Select Important Safety Information

EBGLYSS can cause serious side effects, including:

  • Allergic reactions. EBGLYSS can cause allergic reactions that may sometimes be severe. Stop using EBGLYSS and tell your healthcare provider or get emergency help right away if you get any of the following signs or symptoms:
    • breathing problems or wheezing
    • swelling of the face, lips, mouth, tongue or throat
    • hives
    • itching
    • fainting, dizziness, feeling lightheaded
    • skin rash
    • cramps in your stomach area (abdomen)
  • Eye problems. Tell your healthcare provider if you have any new or worsening eye problems, including eye pain or changes in vision, such as blurred vision.

How EBGLYSS works

EBGLYSS works from inside your body

Eczema inflammation under your skin can lead to the symptoms you see and feel on the outside

When taken as directed, EBGLYSS works around the clock to target eczema inflammation throughout your body that can lead to dry, itchy, and irritated skin.

EBGLYSS targets a protein in the body that causes eczema inflammation

Icon of IL-13

When you have eczema, your body produces too much of a specific protein called IL-13 that can lead to inflammation.

icon of EBGLYSS™ (lebrikizumab-lbkz) targeting IL-13

EBGLYSS is specifically designed to target this protein and help reduce the inflammation that leads to dry, itchy, and irritated skin.

IL=interleukin.

How was EBGLYSS studied?

The efficacy of EBGLYSS was studied in 2 clinical trials. Over 850 adults and children* (ages 12+) with moderate-to-severe eczema that was not well controlled with topical medicines participated.

Goals of the studies at 16 weeks:

  • Clear or almost-clear skin
  • At least 75% clearer skin
  • Meaningful itch relief

Study 1

283

people received EBGLYSS

vs 141 who received placebo for
16 weeks

Study 2

281

people received EBGLYSS

vs 146 who received placebo for
16 weeks

The studies also measured skin clearance and itch relief at 1 year. People who saw skin improvements at 16 weeks either:

  • Continued taking EBGLYSS for an additional 36 weeks
  • Stopped taking EBGLYSS and received placebo for an additional 36 weeks

*Children weighed at least 88 pounds.

Fed up with moderate-to-severe eczema?

Sign up to learn more about a treatment that can help.

SAFETY SUMMARY

Warnings - Do not use EBGLYSS if you are allergic to lebrikizumab-lbkz or to any of the ingredients in EBGLYSS. See the Patient Information leaflet that comes with EBGLYSS for a complete list of ingredients.

Before using
Before using EBGLYSS, tell your healthcare provider about all your medical conditions, including if you:

  • Have a parasitic (helminth) infection.
  • Are scheduled to receive any vaccinations. You should not receive a “live vaccine” if you are treated with EBGLYSS.
  • Are pregnant or plan to become pregnant. It is not known if EBGLYSS will harm your unborn baby. If you become pregnant during treatment with EBGLYSS, you or your healthcare provider can call Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) to report the pregnancy.
  • Are breastfeeding or plan to breastfeed. It is not known if EBGLYSS passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Possible side effects
EBGLYSS can cause serious side effects, including:

  • Allergic reactions. EBGLYSS can cause allergic reactions that may sometimes be severe. Stop using EBGLYSS and tell your healthcare provider or get emergency help right away if you get any of the following signs or symptoms:
    • breathing problems or wheezing
    • swelling of the face, lips, mouth, tongue or throat
    • hives
    • itching
    • fainting, dizziness, feeling lightheaded
    • skin rash
    • cramps in your stomach area (abdomen)
  • Eye problems. Tell your healthcare provider if you have any new or worsening eye problems, including eye pain or changes in vision, such as blurred vision.

The most common side effects of EBGLYSS include:

  • eye and eyelid inflammation, including redness, swelling, and itching
  • injection site reactions
  • shingles (herpes zoster)

These are not all of the possible side effects of EBGLYSS. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

How to take

  • See the detailed “Instructions for Use” that comes with EBGLYSS for information about how to prepare and inject EBGLYSS and how to properly store and throw away (dispose of) used EBGLYSS prefilled pens and prefilled syringes.
  • Use EBGLYSS exactly as prescribed by your healthcare provider.
  • EBGLYSS is given as an injection under the skin (subcutaneous injection).
  • If your healthcare provider decides that you or a caregiver can give the injections of EBGLYSS, you or a caregiver should receive training on the right way to prepare and inject EBGLYSS. Do not try to inject EBGLYSS until you have been shown the right way by your healthcare provider. In children 12 years of age and older, EBGLYSS should be given by a caregiver.
  • If you miss a dose of EBGLYSS, inject the missed dose as soon as possible, then inject your next dose at your regular scheduled time.

Learn more
EBGLYSS is a prescription medicine available as a 250 mg/2 mL injection prefilled pen or prefilled syringe. For more information, call 1-800-545-5979 or go to ebglyss.lilly.com

This summary provides basic information about EBGLYSS but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking to your doctor. Be sure to talk to your doctor or other healthcare provider about EBGLYSS and how to take it. Your doctor is the best person to help you decide if EBGLYSS is right for you.

LK CON BS AD APP

INDICATION

EBGLYSS (EHB-glihs) is an injectable medicine used to treat adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe eczema (atopic dermatitis) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. EBGLYSS can be used with or without topical corticosteroids.

It is not known if EBGLYSS is safe and effective in children less than 12 years of age or in children 12 years to less than 18 years of age who weigh less than 88 pounds (40 kg).